Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Esperion Theraptc
(NQ:
ESPR
)
25.93
USD
+0.48 (+1.89%)
Official Closing Price
Updated: 7:39 PM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Esperion Theraptc
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Esperion to Host Analyst and Investor Day Event on October 17
October 10, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
October 02, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Stocks Under Scanner in the Biotech Space -- Curis, Egalet, and Esperion Therapeutics
September 12, 2017
From
PR Newswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 11, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Prices Public Offering of Common Stock
August 09, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Latest R&D Success, FDA Approvals and Significant Advances in Clinical Trials Boosting Biotech Sector
August 09, 2017
MarketNewsUpdates.com News Commentary
From
PR Newswire
Esperion Announces Proposed Public Offering of Common Stock
August 08, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results
August 08, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin
August 08, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results
August 02, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
July 26, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Breakfast Technical Briefing on Biotech Stocks -- Aurinia Pharma, Esperion Therapeutics, Paratek Pharma, and Verastem
July 20, 2017
From
PR Newswire
Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe
June 26, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion to Present at the JMP Securities 2017 Life Sciences Conference
June 14, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Technical Snapshots for These Biotech Stocks -- Gilead Sciences, Aurinia Pharma, Esperion Therapeutics, and Alexion Pharma
June 07, 2017
From
PR Newswire
Esperion to Present at the Jefferies 2017 Global Healthcare Conference
May 31, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Provides Update on Common Stock Trading Activity
May 22, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
May 19, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 18, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference
May 12, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results
May 04, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
How These Biotech Stocks are Faring? -- ACADIA Pharma, Alexion Pharma, TG Therapeutics, and Esperion Therapeutics
April 24, 2017
From
PR Newswire
Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference
March 28, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective and consistent once-daily oral therapies for...
From
GlobeNewswire News Releases
Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
March 20, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Research Reports Coverage on Healthcare Stocks -- Surgical Care Affiliates, Nxstage Medical, Esperion Therapeutics, and Sierra Oncology
March 09, 2017
From
PR Newswire
Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin
March 07, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific Session
March 06, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Financial Results
February 21, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
February 15, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Trump's Intentions to Streamline Drug-Approval Process Fueling Biotech Optimism
February 07, 2017
From
PR Newswire
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.